Liposomal Formulation of Combinational Antibiotics
- 总结
- Researchers at Purdue University have developed a new liposomal formulation of combinational antibiotics for the treatment of respiratory infections. This new formulation incorporates two synergistic antibiotics to enable maximum bacteria killing against resistant pathogens while significantly reducing irritation to the respiratory tract.
- 技术优势
- Maximum bacteria killing against resistant pathogensReduce resistance development
- 技术应用
- Treatment of respiratory infectionsEradication of Pseudomonas aeruginosa
- 详细技术说明
- Qi ZhouZhou Research Lab
- *Abstract
-
None
- *Background
- Liposomal formulations have been developed for single drugs such as ciprofloxacin but not for combinational antibiotics. Liposomal formulations have shown significant less irritation to the respiratory tract and much better safety in previous clinical trials. Developing liposomal formulations for combinational antibiotics might be beneficial for the treatment of respiratory infections.
- *IP Issue Date
- None
- *IP Type
- Provisional
- *Stage of Development
- Concept validated through theory, simulation, or models
- *Web Links
- Purdue Office of Technology CommercializationPurdue Innovation and EntrepreneurshipQi ZhouZhou Research Lab
- 国家
- United States
- 申请号码
- None
- 国家/地区
- 美国
欲了解更多信息，请点击 这里
